Arimixyl is identified with anastrozole, a selective non-steroidal inhibitor of aromatase. By blocking aromatase activity, anastrozole reduces peripheral estrogen synthesis, particularly after menopause when peripheral conversion becomes an important source of estrogen.
The medicine is principally used as endocrine therapy for certain estrogen-receptor-positive breast cancers. Its estrogen-lowering action can also influence bone metabolism and other estrogen-dependent physiological processes.
The supplied presentation specifies 1mg tablets. Possible treatment-related effects include hot flushes, musculoskeletal discomfort, fatigue, and reductions in bone mineral density, so ongoing clinical assessment can be important.
Reviews
There are no reviews yet.